Эстония - эстонский - Ravimiamet

serb - kaaliumjodiid - tablett - 65mg 20tk; 65mg 10tk

Эстония - эстонский - Ravimiamet

valentis uab - jood - nahalahus - 50mg 1ml 10ml 1tk

Европейский союз - эстонский - EMA (European Medicines Agency)

y-mabs therapeutics a/s - iodine (131i) omburtamab - neuroblastoom - terapeutilised radiofarmatseutilised ühendid - treatment of neuroblastoma.

Европейский союз - эстонский - EMA (European Medicines Agency)

amicus therapeutics europe limited - cipaglucosidase alfa - glükogeeni ladustamise ii tüüpi haigused - muud alimentary seedetrakti ja ainevahetust tooted, - pombiliti (cipaglucosidase alfa) is a long-term enzyme replacement therapy used in combination with the enzyme stabiliser miglustat for the treatment of adults with late-onset pompe disease (acid α-glucosidase [gaa] deficiency).

Эстония - эстонский - Ravimiamet

laboratoire chauvin s.a. - joodpovidoon - silmatilgad, lahus - 5% 0.4ml 20tk

Европейский союз - эстонский - EMA (European Medicines Agency)

novartis europharm limited  - lutetium (177lu) vipivotide tetraxetan - prostatic kasvajad, kastreerimine-vastupidavad - terapeutilised radiofarmatseutilised ühendid - pluvicto in combination with androgen deprivation therapy (adt) with or without androgen receptor (ar) pathway inhibition is indicated for the treatment of adult patients with progressive prostate-specific membrane antigen (psma)-positive metastatic castration-resistant prostate cancer (mcrpc) who have been treated with ar pathway inhibition and taxane based chemotherapy.

Европейский союз - эстонский - EMA (European Medicines Agency)

sanofi b.v. - sutimlimab - hemolysis; anemia, hemolytic, autoimmune - immunosupressandid - enjaymo is indicated for the treatment of haemolytic anaemia in adult patients with cold agglutinin disease (cad).

Европейский союз - эстонский - EMA (European Medicines Agency)

csl behring gmbh - inimese normaalne immunoglobuliin (scig) - immunoloogilise puudulikkuse sündroomid - suguhormoonid ja immunoglobuliinid, - replacement therapy in adults, children and adolescents (0-18 years) in:- primary immunodeficiency syndromes with impaired antibody production (see section 4. - secondary immunodeficiencies (sid) in patients who suffer from severe or recurrent infections, ineffective antimicrobial treatment and either proven specific antibody failure (psaf)* or serum igg level of.

Европейский союз - эстонский - EMA (European Medicines Agency)

csl behring gmbh - human alpha1-proteinase inhibitor - genetic diseases, inborn; lung diseases - antihemorraagilised ained - respreeza on näidustatud hooldusraviks, et aeglustada emfüseemi progresseerumist täiskasvanutel, kellel on dokumenteeritud raske alfi-1-proteinaasi inhibiitori puudus (e. genotüübid pizz, piz (null), pi (null, null), pisz). patsiendid peavad olema optimaalne farmakoloogilise ja farmakoloogiline ravi ja progresseeruv haigus (e ilmnenud. madalam forsseeritud ekspiratoorse mahu (fev1) sekundis ennustati, häiritud kõndimine võimsuse või ägenemiste arvu suurenemine) kasutati α1-kopsuhaiguse näidustuse korral ravis kogenud tervishoiutöötajaga.

Эстония - эстонский - Ravimiamet

teva b.v. - fosinopriil+hüdroklorotiasiid - tablett - 20mg+12,5mg 50tk; 20mg+12,5mg 100tk; 20mg+12,5mg 14tk; 20mg+12,5mg 60tk